BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

774 related articles for article (PubMed ID: 18332466)

  • 21. [Treatment outcome and prognosis of autologous hematopoietic stem cell transplantation combined with high dose radiotherapy/chemotherapy in 22 patients with nasal NK/T cell lymphoma].
    Cui XZ; Wang HQ; Liu XM; Zhang HL; Li W
    Zhonghua Xue Ye Xue Za Zhi; 2007 Sep; 28(9):609-11. PubMed ID: 18246818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy.
    Campbell BA; Connors JM; Gascoyne RD; Morris WJ; Pickles T; Sehn LH
    Cancer; 2012 Sep; 118(17):4156-65. PubMed ID: 22252721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
    Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
    Rodríguez J; Conde E; Gutiérrez A; Arranz R; Gandarillas M; Leon A; Ojanguren J; Sureda A; Carrera D; Bendandi M; Moraleda J; Ribera JM; Albo C; Morales A; García JC; Fernández P; Cañigral G; Bergua J; Caballero MD;
    Eur J Haematol; 2007 Apr; 78(4):290-6. PubMed ID: 17378891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas.
    Girinsky T; Lapusan S; Ribrag V; Koscielny S; Ferme C; Carde P
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):476-9. PubMed ID: 15667970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.
    Lancet JE; Rapoport AP; Brasacchio R; Eberly S; Raubertas RF; Linder T; Muhs A; Duerst RE; Abboud CN; Packman CH; DiPersio JF; Constine LS; Rowe JM; Liesveld JL
    Bone Marrow Transplant; 1998 Aug; 22(3):265-71. PubMed ID: 9720740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Localized radiation increases morbidity and mortality after TBI-containing autologous stem cell transplantation in patients with lymphoma.
    Emmanouilides C; Asuncion DJ; Wolf C; Scott S; Territo M
    Bone Marrow Transplant; 2003 Nov; 32(9):863-7. PubMed ID: 14561985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
    Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma.
    De Sanctis V; Finolezzi E; Osti MF; Grapulin L; Alfò M; Pescarmona E; Berardi F; Natalino F; Moleti ML; Di Rocco A; Enrici RM; Foà R; Martelli M
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1154-60. PubMed ID: 18472357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term survival following radiotherapy and cytarabine chemotherapy for sporadic primary central nervous system lymphoma.
    Pöttgen C; Stuschke M; Stüben G; Schmitz A; Schwechheimer K; Wacker HH; Rauhut F; Kleuker S; Wilhelm H; Grehl S; Fehlings T
    Strahlenther Onkol; 2003 Sep; 179(9):626-32. PubMed ID: 14628129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors.
    Modak S; Gardner S; Dunkel IJ; Balmaceda C; Rosenblum MK; Miller DC; Halpern S; Finlay JL
    J Clin Oncol; 2004 May; 22(10):1934-43. PubMed ID: 15143087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience.
    Mazzarotto R; Boso C; Vianello F; Aversa MS; Chiarion-Sileni V; Trentin L; Zambello R; Muzzio PC; Fiore D; Sotti G
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):823-9. PubMed ID: 17379431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT).
    Rosenbluth BD; Yahalom J
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1185-91. PubMed ID: 16682133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma.
    Goodman KA; Riedel E; Serrano V; Gulati S; Moskowitz CH; Yahalom J
    J Clin Oncol; 2008 Nov; 26(32):5240-7. PubMed ID: 18809615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required?
    Laskar S; Bahl G; Muckaden MA; Nair R; Gupta S; Bakshi A; Gujral S; Shet T; Shrivastava SK; Dinshaw KA
    Cancer; 2007 Aug; 110(4):816-23. PubMed ID: 17582622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
    Gao Y; Huang HQ; Lin XB; Cai QQ; Pan ZH; Wang BF; Bu Q
    Ai Zheng; 2007 Aug; 26(8):909-13. PubMed ID: 17697558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.
    Bradfield SM; Douglas JG; Hawkins DS; Sanders JE; Park JR
    Cancer; 2004 Mar; 100(6):1268-75. PubMed ID: 15022296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.
    Tsai D; Moore H; Hardy C; Porter D; Loh E; Vaughn D; Luger S; Schuster S; Stadtmauer E
    Bone Marrow Transplant; 1999 Sep; 24(5):521-6. PubMed ID: 10482937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
    Margolin KA; Doroshow JH; Frankel P; Chow W; Leong LA; Lim D; McNamara M; Morgan RJ; Shibata S; Somlo G; Twardowski P; Yen Y; Kogut N; Schriber J; Alvarnas J; Stalter S
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):903-11. PubMed ID: 16275593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease.
    Mundt AJ; Sibley G; Williams S; Hallahan D; Nautiyal J; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):261-70. PubMed ID: 7673013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.